Novo Nordisk raises sales and operating profit outlook for 2023

Novo Nordisk raises sales and operating profit outlook for 2023

Novo Nordisk today announced the sales and operating profit growth at constant exchange rates (CER) for the first three months of 2023 and that the full-year sales and operating profit outlook at CER has been raised.                          

In the first three months of 2023, Novo Nordisk’s sales increased by 25% and operating profit increased by 28%, both at CER. Wholesaler inventory movements in the US positively impacted sales growth.

The sales outlook for 2023 is raised, primarily reflecting Wegovy® prescription trends in the first quarter and higher full-year expectations for sales of Wegovy® in the US. Furthermore, a second contract manufacturer is now ready to begin production, thereby increasing Wegovy® supply capacity.

The updated sales outlook also reflects higher full-year expectations for Ozempic® sales, mainly in the US, following accelerated volume growth of the GLP-1 class.    

Novo Nordisk’s full disclosure of the financial results for the first three months of 2023 will be published on 4 May 2023.

The above expectations are based on assumptions including those described on pages 16 and 17 of the Financial report for the period 1 January 2022 to 31 December 2022 (Company Announcement No 5/2023).  

The forward-looking statements on page 24 of the Financial report for the period 1 January 2022 to 31 December 2022 (Company Announcement No 5/2023) also apply to this company announcement.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. 

Source link:https://www.novonordisk.com